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Abstract
Paraoxonase (PON1) is a calcium-dependent esterase,
closely associated with high-density lipoprotein (HDL)-con-
taining apolipoprotein AI, that has been reported to confer
antioxidant properties on HDL by decreasing the accumula-
tion of lipid peroxidation products. PON1 activity is under
genetic and environmental regulation and appears to vary
widely among individuals and populations. PON1 enzyme
activity for paraoxon as a substrate is modulated by a num-
ber of polymorphisms at the PON1 locus in humans. One of
them is the PON1-192 genetic polymorphism that comprises
PON1 Q, an isoform which has a glutamine at position 192,
and shows a low activity towards paraoxon hydrolysis, while
the high paraoxon-activity PON1 R isoform contains an argi-
nine at position 192. The association of PON1 activity levels
with atherosclerosis in human, animal and in vitro studies is
consistent and exciting. Therefore, there is an obvious need
to know whether environmental factors can influence serum
PON1. The genetic association studies for PON1 and ather-
osclerosis are less consistent, since the PON1 polymor-
phisms probably only produce an effect on coronary heart
disease risk in particular subgroups of subjects in the pres-
ence of additional factors. It is particularly important to study
gene-environmental interactions that may modulate pheno-
typic expression of PON1 in different populations.
Resum
La paraoxonasa (PON1) és una esterasa calciodepenent
estretament associada a les lipoproteïnes d’alta densitat
(HDL) que contenen apolipoproteïna AI, i s’ha descrit que
dóna capacitat antioxidant a les HDL, amb la qual cosa dis-
minueix l’acumulació dels lipoperòxids. L’activitat PON1
està sota control genètic i ambiental, i varia àmpliament en-
tre individus i poblacions. L’activitat PON1 del paraoxon
com a substrat és modulada per diversos polimorfismes en
el locus PON1 dels humans. Un d’aquests polimorfismes és
el PON1-192, que conté PON1 Q, una isoforma amb baixa
activitat per la hidròlisi de paraoxon que té una glutamina a
la posició 192, mentre que la isoforma R d’alta activitat con-
té una arginina a la posició 192. L’associació de l’activitat
PON1 amb l’arteriosclerosi en estudis humans, animals i in
vitro és prou consistent. Per tant, cal conèixer els factors
que poden influenciar la PON1 sèrica. Els estudis genètics
d’associació són menys consistents, probablement perquè
els polimorfismes de la PON1 tenen només efecte en el risc
de malaltia cardíaca coronària en grups particulars d’indivi-
dus amb la presència de factors addicionals. És particular-
ment important estudiar les interaccions gen-ambient que
poden modular l’expressió fenotípica de la PON1 en dife-
rents poblacions.
Introduction: on the physiological function of
paraoxonase
Paraoxonase (PON1) is a serum enzyme synthesized by the
liver [1]. PON1 has been extensively studied in the sphere of
toxicology because of its capacity to hydrolyze synthetic
organophosphate compounds. These include metabolic
products widely used as pesticides and nerve gases such
as sarin [1]. Besides the well-known protective function of
the ability of PON1 to hydrolyze organophosphate nerve
agents and insecticides, some years ago it was proposed
that PON1 may be involved in lipid metabolism [1].We now
have several pieces of evidence that support this hypothe-
sis. PON1 is a calcium-dependent esterase closely associ-
ated with high-density lipoprotein (HDL)-containing
apolipoprotein AI [1]. Several lines of evidence are emerg-
ing which demonstrate that HDL can prevent oxidation of
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low-density lipoprotein (LDL), and that some oxidized LDL
phospholipids are physiological substrates for serum PON1
[2,3]. Therefore, serum PON1 may be able to offer protection
against the oxidation of the LDL phospholipids and several
laboratories have undertaken basic research in this impor-
tant direction.
Serum paraoxonase and lipoprotein oxidation
Human and animal studies strongly support the hypothesis
that oxidative modification of LDLs performs a crucial func-
tion in the pathogenesis of atherosclerosis [4]. Therefore,
mechanisms preventing LDL oxidation appear to be an-
tiatherogenic (Figure 1). In this respect, HDL-associated
PON1 may be a major defence barrier against lipid perox-
ides from oxidized LDLs [5]. The ability of HDL to attenuate
the oxidation of LDL is largely attributable to PON1 [5]. In
vivo, PON1 may directly act on lipid peroxides or, more like-
ly, lipid peroxides are first transferred to HDL and then de-
stroyed by PON1 [6]. It has been shown that purified PON1
can prevent pro-atherosclerotic effects of oxidized LDL
when incubated in a vascular cell culture system [7]. The
most convincing evidence produced for an anti-oxidative
function of PON1 comes from the lack of protection of the
HDL fraction obtained from PON1 knock-out mice, com-
pared with HDL from the wild-type mice [8]. Clearly then,
there is an obvious need to know whether environmental fac-
tors, such as diet, physical activity or therapeutic factors,
can influence serum PON1 activity or protein concentra-
tions.
Paraoxonase activity and atherosclerosis
There are some observations [9,10] relating lower PON1 ac-
tivity levels in myocardial infarction (MI) patients compared
to controls. These findings have been confirmed by our lab-
oratory in one study using 280 consecutive myocardial in-
farction patients and 396 control subjects from the REGI-
COR study (Sentí M et al, unpublished work). PON1 is able
to hydrolyze a number of substrates such as paraoxon and
phenyl acetate; however, the physiological substrate of
PON1 remains to be discovered. Uncertainties relating to
whether PON1 activity, as measured by paraoxon hydroly-
sis, reflects the antioxidant capacity of the enzyme have re-
cently been reported [11]. However, in addition to low PON1
activity in patients who had suffered from MI, a significant
decrease in PON1 activity toward paraoxon hydrolysis has
been shown in diseases with accelerated atherogenesis
such as familial hypercholesterolemia [12,13] and diabetes
mellitus [12,14]. Therefore, with a physiological substrate to
be defined, the function of PON1 activity measured by
paraoxon hydrolysis remains to be clearly understood.
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Figure 1. Relationship of the production of free radicals, lipidic peroxidation and the antioxidant systems. Free radicals generated from oxida-
tive stress react with LDL particles, thus oxidizing vitamin E and the lipidic component of LDL. The antioxidant systems prevent LDL oxidation
by reducing oxidized compounds. Apo B 100: apolipoprotein B 100; PUFA: polyunsaturated fatty acids; LDL: low density lipoproteins; Eox: ox-
idized vitamin E; LDLox: oxidized LDL; apoB 100-100ox: apolipoprotein B 100 oxidized; PUFAox: polyunsaturated fatty acids oxidized; Vit Cox: vi-
tamin C oxidized; Gssg: oxidized glutathion; GsH: reduced glutathion; HDL: high-density lipoprotein; SOD: superoxide dismutase; GPX: glu-
tathion reductase; CAT: catalase.
In this respect, one point of interest concerns the inactiva-
tion of PON1 in the presence of oxidative stress. PON1 activ-
ity has been shown to be reduced in the course of oxidative
incubation with Cu++ induced peroxidation of LDL [11]. Oxi-
dized LDL appears to inactivate PON1 through interactions
between the enzyme-free sulfhydril group and oxidized
lipids which are formed during LDL oxidation [15]. There is
evidence of an increase in lipid peroxidation products in pa-
tients with coronary heart disease [16]. There are also some
observations suggesting that a low PON1 activity is likely to
be present at the time of acute MI [10]. In this respect, PON1
activity may be partially inactivated in the presence of oxida-
tive stress, as probably occurs in patients with coronary
heart disease (CHD) or atherosclerosis. Therefore, although
the possibility that PON1 decreases as a consequence of an
acute phase cannot be excluded, neither can the possibility
be ruled out that low PON1 activity in myocardial infarction is
reflecting an increased oxidative stress.
The paraoxonase gene
PON1 activity is under genetic and environmental regulation
and appears to vary widely among individuals and popula-
tions. One molecular basis of the variations in PON1 activity
is a polymorphism in the PON1 gene located at position 192
of chromosome 7 which is clustered with at least two other
related genes, PON2 and PON3 [17]. PON1-192 genetic
polymorphism comprises PON1 Q, an isoform with low activ-
ity towards paraoxon hydrolysis, which has a glutamine at
position 192, while the high-activity PON1 R isoform contains
an arginine at position 192 [3]. Another polymorphism in hu-
man PON1 gene at amino acid 55, the PON1-55 polymor-
phism, which comprises a leucine (L) to methionine (M) sub-
stitution, seems to be more representative of PON1 protein
concentration [18]. However, it has also been shown that
modulates PON1 activity independently of the PON1-192
polymorphism in healthy people [18]. Individuals homozy-
gous for the MM allele appear to have lower PON1 activity
toward paraoxon compared with LL homozygotes. PON2
gene has two common polymorphisms designated G/A 148
and C/S 311 [19,20]. The genetic variant of PON2 gene at
codon 148 has been found to be associated with elevated
fasting plasma glucose in subjects with non-insulin-depen-
dent diabetes mellitus [21]. Remarkably, Leviev and James
[22] have recently identified three polymorphisms in the pro-
moter region of the human PON1 gene which appear to have
a great impact on PON1 activity levels and PON1 concentra-
tions. This finding contributes to establishing a genetic basis
for variations in PON1 levels, with physiological importance
for the genetic nature of the antioxidant properties of HDL.
Paraoxonase1 polymorphisms and
atherosclerosis
The report by Ruiz et al [23] was the first in a series of studies
on PON1-192 gene polymorphism and CHD. Surprisingly, it
was the R allele (high activity towards paraoxon) that was
positively associated with the presence of CHD. Reviewing
these studies reveals discrepancies even in those conduct-
ed in the same ethnic population [24,25]. In one study car-
ried out in the USA [26], the R allele was associated with
CHD, but in Europe four studies failed to show such an asso-
ciation [27,30]. This variability in results suggests that gene-
environment and/or gene-gene interactions might modulate
the relationship between PON1-192 polymorphism and
CHD.
In genetic associations several geographic differences
may exist and the most convincing evidence is reproducibil-
ity in different populations. We therefore conducted a case-
control study in Girona, Spain, to answer the question of
whether the Gln/Arg 192 PON1 polymorphism is associated
with increased risk of CHD in our population and how dia-
betes mellitus, associated with high oxidative risk, influ-
ences such an association [31]. One hundred and fifty-six
consecutive MI patients and 310 age- and sex-matched
control subjects were studied. There were no differences in
the distribution of genotype and allele frequencies between
patients and controls. The odds ratios for diabetes and dys-
lipemia in control and patients stratified by genotype groups
were compared. Whereas dyslipemic status was significant-
ly related to myocardial infarction in QQ homozygotes and R
carriers, diabetes mellitus was significantly associated with
MI only in R-carrier subjects. In logistic regression analysis,
diabetic R carriers showed more than a two and a half-fold
increase in MI risk compared with nondiabetic R carriers
(OR: 2.65, P<0.05). These data indicate that the R allele of
the PON1-192 polymorphism is not an independent risk fac-
tor for MI in our population. However, there is an interaction
between this polymorphism and diabetes mellitus consisting
of increased MI risk in diabetic patients with the R allele.
There are several possible explanations for disparities
among studies. First, admixture of genetically heteroge-
neous populations could explain some contradictory results,
but it cannot explain the differences found in studies con-
ducted in the same ethnic population. Second, discrepan-
cies among studies may be due to a bias in patient selec-
tion. Third, PON1-192 polymorphism may reflect an
underlying unknown mutation responsible for cardiovascu-
lar risk located in the same gene or in others. It is also con-
ceivable that PON1-192 polymorphism only produces an ef-
fect on coronary heart disease risk among particular
subgroups of subjects in the presence or absence of addi-
tional factors. In this respect, the possible deleterious effect
of PON1-192 polymorphism may be overexpressed when a
particular genetic variant and a particular oxidative condi-
tion coexist. If this is true, it would be necessary to analyze
the effect of PON1-192 polymorphism on different strata of
anthropometric, life style and other environmental or meta-
bolic factors. We have conducted some studies on the rela-
tionship of increased oxidative conditions, such as smoking
and aging, and altered metabolic conditions, such as HDL-
deficiency status and PON1-192 polymorphism on MI risk.
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Low HDL concentration is firmly established as one of the
principal cardiovascular risk factors. PON1 may be respon-
sible for part of the anti-oxidant properties of this lipoprotein.
Since HDL particle is strongly associated with PON1, this
lipoprotein emerges as a firm candidate to be analyzed in
relation to PON1 activity and PON1-192 genotypes. The as-
sociation of PON1 with HDL suggests that impaired serum
concentrations of the lipoprotein could have consequences
for susceptibility to oxidative stress. Since PON1-192 genet-
ic polymorphism strongly influences PON1 activity towards
paraoxon, we tested the hypothesis that this polymorphism
may modulate the MI risk associated with low HDL-choles-
terol concentrations (Sentí M et al, unpublished work). Two
hundred and eighty consecutive MI patients and 396 control
subjects were studied. To determine whether the HDL-defi-
ciency status was differentially associated with MI risk
among PON1-192 genotypes, logistic regression analyses
were performed in the overall group of the study subjects
and in each genotype (Figure 2). Models were adjusted for
age, sex, diabetes mellitus, hypertension and smoking. In
the overall population, decreased HDL cholesterol concen-
tration conferred a MI risk of 2.56 (P=0.0001) compared to
normal HDL levels. The risk increased to 4.51 (P<0.0001) in
QQ homozygous HDL-deficient subjects relative to QQ ho-
mozygotes with normal HDL levels, decreased to 1.83
(P=0.1046) in QR heterozygote HDL-deficient subjects and
also lowered to 1.41 (P=0.6243) in RR homozygote HDL-de-
ficient individuals compared to RR carriers with normal HDL-
cholesterol concentration. Therefore, the effect of PON1-192
genotypes on the association of low HDL-cholesterol levels
with MI was gene-dosage related. These observations lead
to an interesting hypothesis: PON1-192 genetic polymor-
phism modulates the non-fatal MI risk associated with de-
creased HDL cholesterol levels. The risk of non-fatal MI is in-
creased in HDL-deficiency states principally among
subjects carrying the low paraozon-activity QQ PON1-192
genotype.
Some lines of evidence indicate that with advancing age
there are inflammatory modifications of the arterial wall and
increased susceptibility to oxidative stress in the suben-
dothelial space which are likely to accelerate and increase
severity of atherosclerosis in elderly subjects [32]. Results
are controversial, but if protection by PON1 against LDL oxi-
dation is affected by the PON1-192 polymorphism, it is con-
ceivable that age-related myocardial infarction (MI) risk
would be of different magnitude in subjects carrying the Q
allele compared to those with the R allele. We conducted a
study to determine whether PON1 activity and PON1-192
genetic variants have a different impact on MI risk among MI
patients and controls stratified by tertiles of age distribution:
young subjects ≤50 years), middle-aged individuals (51 to
62 years) and subjects aged 63 to 74 (Sentí M et al, unpub-
lished work). It is noteworthy that a decline in PON1 activity
levels with advancing age was observed in subjects of both
study groups carrying the low-activity QQ genotype, particu-
larly in MI patients. We found that PON1 activity levels and
age negatively correlated only in patients, and that the mag-
nitude of this negative association was higher in MI patients
carrying the more prevalent QQ and QR genotypes than in
controls carrying the same genotypes. We also found that
homozygote subjects for the Q allele aged over 62 showed a
more than four-fold increase in MI risk compared to younger
QQ homozygotes, and also with respect to older RR ho-
mozygotes. The effect of genotypes on the association of the
oldest age-category with MI risk was gene-dosage related.
The effect was highest in QQ genotype, intermediate in the
QR genotype, and lowest in the RR genotype. Our observa-
tions lead to the following reasoning: the QQ genotype,
which is associated with low PON1 activity, may be ade-
quate to prevent lipid peroxidation in young individuals or in
older subjects without atherosclerosis. However, the low-ac-
tivity QQ genotype may have its antioxidant capacity ex-
ceeded when there is a coexistence of advanced age,
which probably compromises PON1 function, and coronary
heart disease, which still inactivates more PON1 activity.
Smokers seem to have great susceptibility to low-density
lipoprotein oxidation, which probably contributes to their in-
creased risk of atherosclerosis [33]. We investigated
whether smoking, assessed by the cigarette packs smoked
per year, has a differential effect related to PON1-192 geno-
types on myocardial infarction (MI) risk in a case-control
study (34). As expected, smokers or ex-smokers of the high-
er tertiles of cigarette packs smoked per year showed a sig-
nificantly increased MI risk. The odds ratios for the effect of
smoking on MI risk were then calculated in subjects strati-
fied by the PON1-192 genotype groups. Whereas catego-
rized cigarette packs smoked per year were not related to
increased MI risk in R carriers, in QQ homozygotes they
were significantly associated with an increased MI risk (Fi-
gure 3). This was higher among those in the higher tertile of
cigarette packs smoked per year compared to those of the
lower tertile (P for trend <0.001). The effects observed ap-
pear to show links between smoking, the genotype QQ of
the PON1-192 polymorphism and increased risk of MI. Since
PON1 is thought to exert an antioxidant effect and smoking
is prone to oxidative stress, the risk of MI associated with
smoking may be increased in subjects homozygous for the
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Figure 2. Adjusted odds ratios for the effect of low HDL cholesterol
concentrations on myocardial infarction risk in the overall group of
the study subjects and in subjects stratified by PON1-192 geno-
types. Models adjusted for diabetes, hypertension, age, sex and
smoking.
low-activity PON1 QQ genotype. This increased MI risk ap-
pears to be time- and dose-dependent.
Some authors have failed to find associations between
the variation in PON1 gene and changes in lipoprotein con-
centrations [27]. However, others have found significant as-
sociations of PON1-192 genetic variants with changes in
HDL-cholesterol levels and in triglyceride concentrations in
a relatively genetically-isolated population [35,36]. Since
these changes are also characteristic of physical activity,
and because it is particularly important to study gene-envi-
ronmental interactions that may modulate phenotypic ex-
pression of PON1 in different populations, we attempted to
ascertain whether an interaction which modifies serum
lipoproteins exists between PON1-192 genetic polymor-
phism and physical activity [37]. Overall, our results sug-
gested no influence of PON1-192 genetic variation on lipids
and lipoproteins. However, physical activity was associated
with increased HDL-cholesterol levels and decreased
triglyceride levels only in men carrying the R allele (Fi-
gure 4). R carriers included in the lower physical activity ter-
tile had an HDL-cholesterol mean concentration significantly
lower than QQ homozygous men in the same physical activ-
ity category. In contrast, R carriers of the second tertile
achieved HDL-cholesterol levels similar to those of QQ sub-
jects and, interestingly, better serum triglycerides. Very ac-
tive R carriers showed the most favorable lipid profile in this
genotype group. Therefore, the existence of a single R allele
seems to strongly impair the lipid profile, particularly HDL-
cholesterol concentrations, in men if physical activity is not
regularly undertaken, but our results also suggest that with
moderate increases in physical activity the beneficial effect
on lipids is already obtained in subjects with the R allele.
Conclusions
PON1 is an HDL-associated enzyme that protects lipopro-
teins from oxidative modifications. PON1, which hydrolyzes
organophosphates such as paraoxon, appears to use phos-
pholipids on LDL as a physiological substrate. The associa-
tion of PON1 activity levels with atherosclerosis in human,
animal and in vitro studies is consistent and exciting. There-
fore, there is an obvious need to know whether environmen-
tal factors can influence serum PON1. The genetic associa-
tion studies for PON1 are less consistent, since probably the
PON1 polymorphisms only produce an effect on coronary
heart disease risk among particular subgroups of subjects in
the presence of additional factors. Until now, in those stud-
ies in which an association of the PON1-192 polymorphism
with coronary heart disease was observed, it was paradoxi-
cally the high paraoxon-activity R allele that was associated.
However, we recently reported that the risk of MI associated
with a classical risk factor such as smoking may be in-
creased in subjects homozygous for the low paraoxon-activ-
ity PON1 QQ genotype. Furthermore, we recently found that
the QQ genotype may represent an additional risk factor for
MI in subjects with low HDL cholesterol levels.
Much more remains to be learnt about the possible rele-
vance of the PON1 gene and its product. It is conceivable
that an antioxidant diet, which seems to perform a crucial
function in the lower prevalence of coronary heart disease in
the Mediterranean area, may influence PON1 activity. It is
also particularly important to study gene-environmental in-
teractions that may modulate phenotypic expression of
PON1 in different populations.
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